Filtered By:
Infectious Disease: SARS

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 121 results found since Jan 2013.

Suppression of SARS-CoV-2 Replication with Stabilized and Click-Chemistry Modified siRNAs
Angew Chem Int Ed Engl. 2022 Jul 8. doi: 10.1002/anie.202204556. Online ahead of print.ABSTRACTTThe emergence of more transmissible or aggressive variants of SARS-CoV-2 requires the development of antiviral medication that is quickly adjustable to evolving viral escape mutations. Here we report the synthesis of chemically stabilized small interfering RNA (siRNA) against SARS-CoV-2. The siRNA can be further modified with receptor ligands such as peptides using Cu(I)-catalysed click-chemistry. We demonstrate that optimized siRNAs can reduce viral loads and virus-induced cytotoxicity by up to five orders of magnitude in cell ...
Source: Angewandte Chemie - July 8, 2022 Category: Chemistry Authors: Franziska R Traube Marcel Stern Annika J T ölke Martina Rudelius Ernesto Mej ías-Pérez Nada Raddaoui Beate M K ümmerer C éline Douat Filipp Streshnev Manuel Albanese Paul R Wratil Yasmin V G ärtner Milda Nainyt ė Grazia Giorgio Stylianos Michalakis Source Type: research

To accelerate the Zika beat: candidate design for RNA interference-based therapy.
Abstract Zika virus infection is associated with the development of severe neurological disorders in adults and newborns. Although at the moment Zika virus outbreak is not threatening to become again an emergency, infection cases are still being sporadically reported and there is still no effective therapy available. A possible treatment to suppress Zika replication is represented by short interfering RNAs (siRNAs), since they have been successfully used even against Ebola, H5N1 and SARS viruses and clinical trials of siRNA-based drugs are ongoing. In order to speed up the time consuming experimental validation of...
Source: Virus Research - July 18, 2018 Category: Virology Authors: Giulietti M, Righetti A, Cianfruglia L, Šabanović B, Armeni T, Principato G, Piva F Tags: Virus Res Source Type: research

Prophylactic intranasal administration of lipid nanoparticle formulated siRNAs reduce SARS-CoV-2 and RSV lung infection
J Microbiol Immunol Infect. 2023 Mar 8:S1684-1182(23)00068-3. doi: 10.1016/j.jmii.2023.02.010. Online ahead of print.ABSTRACTRNA interference (RNAi) is an emerging and promising therapy for a wide range of respiratory viral infections. This highly specific suppression can be achieved by the introduction of short-interfering RNA (siRNA) into mammalian systems, resulting in the effective reduction of viral load. Unfortunately, this has been hindered by the lack of a good delivery system, especially via the intranasal (IN) route. Here, we have developed an IN siRNA encapsulated lipid nanoparticle (LNP) in vivo delivery system...
Source: Journal of Microbiology, Immunology, and Infection - March 18, 2023 Category: Microbiology Authors: Aroon Supramaniam Yaman Tayyar Daniel T W Clarke Gabrielle Kelly Dhruba Acharya Kevin V Morris Nigel A J McMillan Adi Idris Source Type: research

SARS-CoV-2 N Protein Triggers Acute Lung Injury via Modulating Macrophage Activation and Infiltration in in vitro and in vivo
CONCLUSION: SARS-CoV-2 and its N protein but not S protein induced acute lung injury and systemic inflammation, which was closely related to macrophage activation, infiltration and release cytokines.PMID:37143821 | PMC:PMC10153437 | DOI:10.2147/JIR.S405722
Source: Cancer Control - May 5, 2023 Category: Cancer & Oncology Authors: Dengming Lai Kun Zhu Sisi Li Yi Xiao Qi Xu Yisheng Sun Pingping Yao Daqing Ma Qiang Shu Source Type: research

Nucleic Acid-Based Treatments Against COVID-19: Potential Efficacy of Aptamers and siRNAs
Despite significant efforts, there are currently no approved treatments for COVID-19. However, biotechnological approaches appear to be promising in the treatment of the disease. Accordingly, nucleic acid-based treatments including aptamers and siRNAs are candidates that might be effective in COVID-19 treatment. Aptamers can hamper entry and replication stages of the SARS-CoV-2 infection, while siRNAs can cleave the viral genomic and subgenomic RNAs to inhibit the viral life cycle and reduce viral loads. As a conjugated molecule, aptamer–siRNA chimeras have proven to be dual-functioning antiviral therapy, acting both as ...
Source: Frontiers in Microbiology - November 8, 2021 Category: Microbiology Source Type: research

Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spread
Nucleic Acids Res. 2021 Dec 20:gkab1248. doi: 10.1093/nar/gkab1248. Online ahead of print.ABSTRACTA promising approach to tackle the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) could be small interfering (si)RNAs. So far it is unclear, which viral replication steps can be efficiently inhibited with siRNAs. Here, we report that siRNAs can target genomic RNA (gRNA) of SARS-CoV-2 after cell entry, and thereby terminate replication before start of transcription and prevent virus-induced cell death. Coronaviruses replicate via negative sense RNA intermediates using a unique discontinuous transcription process. ...
Source: Cell Research - December 20, 2021 Category: Cytology Authors: Shubhankar Ambike Cho-Chin Cheng Martin Feuerherd Stoyan Velkov Domizia Baldassi Suliman Qadir Afridi Diana Porras-Gonzalez Xin Wei Philipp Hagen Nikolaus Kneidinger Mircea Gabriel Stoleriu Vincent Grass Gerald Burgstaller Andreas Pichlmair Olivia M Merke Source Type: research

RNAi suppressor: The hidden weapon of SARS-CoV.
Abstract The two biological evidences to endorse the antiviral activity of RNA interference (RNAi) are biogenesis of viral-siRNA (v-siRNA) by the host and encoding of RNAi-suppressor protein by viral genome. It has been recently established that mammals and mammalian cell lines mount antiviral RNAi to defend themselves against the invading viruses. The large part of viral pathogenicity is also due to the RNAi suppressor proteins. In this context it is only natural to ask what kinds of RNAi suppressors are encoded by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the central character of the pres...
Source: Journal of Biosciences - July 29, 2020 Category: Biomedical Science Authors: Karjee S, Mukherjee SK Tags: J Biosci Source Type: research

Viruses, Vol. 13, Pages 2030: Inhibition of SARS-CoV-2 Replication by a Small Interfering RNA Targeting the Leader Sequence
Drosten Jens Kurreck Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected almost 200 million people worldwide and led to approximately 4 million deaths as of August 2021. Despite successful vaccine development, treatment options are limited. A promising strategy to specifically target viral infections is to suppress viral replication through RNA interference (RNAi). Hence, we designed eight small interfering RNAs (siRNAs) targeting the highly conserved 5’-untranslated region (5’-UTR) of SARS-CoV-2. The most promising candidate identified in initial reporter assays, termed siCoV6, targets the ...
Source: Viruses - October 8, 2021 Category: Virology Authors: Beatrice Tolksdorf Chuanxiong Nie Daniela Niemeyer Viola R öhrs Johanna Berg Daniel Lauster Julia M. Adler Rainer Haag Jakob Trimpert Benedikt Kaufer Christian Drosten Jens Kurreck Tags: Article Source Type: research

Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways
CONCLUSION: LNP formulations enable the delivery of RNA payloads into human airway epithelial cells, and in the murine respiratory system; they can be delivered to nasal mucosa and lower respiratory tract via intranasal delivery. The composition of helper lipids in LNPs crucially modulates transfection efficiencies in airway epithelia, highlighting their importance in effective delivery of therapeutic products for airways diseases.PMID:35688311 | DOI:10.1016/j.ejps.2022.106234
Source: Cancer Control - June 10, 2022 Category: Cancer & Oncology Authors: A Tam J Kulkarni K An L Li D R Dorscheid G K Singhera P Bernatchez Gsd Reid Kyt Chan D Witzigmann P R Cullis D D Sin C J Lim Source Type: research